In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Inozyme Pharma (INZY – Research Report), with a price target of $20.00. The company’s shares opened today at $3.41.
White covers the Healthcare sector, focusing on stocks such as Clovis Oncology, G1 Therapeutics, and ChemoCentryx. According to TipRanks, White has an average return of -14.7% and a 32.96% success rate on recommended stocks.
Inozyme Pharma has an analyst consensus of Strong Buy, with a price target consensus of $22.00, a 545.16% upside from current levels. In a report released today, Needham also reiterated a Buy rating on the stock with a $23.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $17.55 and a one-year low of $3.15. Currently, Inozyme Pharma has an average volume of 182.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
Read More on INZY:
- H.C. Wainwright Remains a Buy on Tempest Therapeutics (TPST)
- Richardson Electronics Participating in 2022 KIEES Summer Academic Conference in South Korea
- Security National Financial Corporation Reports Financial Results for the Quarter Ended June 30, 2022
- Here’s Why Revolve Stock was Down Monday Morning
- LNK’s Awakening: Cybercriminals Moving from Macros to Shortcut Files to Access Business PCs
